Trust Signals
Key Takeaways
- No human RCT has established a validated BPC-157 dose; all human protocols are extrapolations from rodent data or researcher convention.
- Rat studies used approximately 10 mcg/kg; allometric scaling (6.2x surface area factor) yields roughly 1.6 mcg/kg in humans, but empirical researcher use is 2.5 to 5.5 mcg/kg, an unresolved discrepancy.
- For a 200 lb (90 kg) male, allometric math gives ~144 mcg per dose; researcher convention is 250 to 500 mcg per dose.
- BPC-157 purity varies substantially by vendor; HPLC above 98% and mass spectrometry confirming 1419.53 Da molecular weight are the minimum COA requirements.
- The FDA restricted BPC-157 from compounded medications in 2023 to 2024; it is sold only as a research chemical in the US, which means it cannot legally be marketed for human use.
Direct Answer: What Is the BPC-157 Dosage?
Table of Contents
- Evidence Ledger: What the Data Actually Supports
- Mechanism and Specific Numbers
- BPC-157 Dosage Chart
- BPC-157 Dosage Per Body Weight
- BPC-157 + TB-500 Stack Dosage
- What Most Dosage Pages Get Wrong
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head: BPC-157 vs. Alternatives
- Operational Label and COA Literacy
- FAQ
- Sources
Evidence Ledger: What Does the Data Actually Support?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Accelerates tendon and ligament healing | Multiple rat/rabbit studies (e.g., Pevec et al. 2010, Brcic et al. 2009) | Positive | Moderate (animal only) |
| GI mucosal protection and ulcer healing | Rat studies; one small human case report series (Sikiric et al.) | Positive | Moderate (animal) / Very Low (human) |
| Upregulates VEGF and growth factor receptors | Cell culture and animal mechanistic studies | Positive (mechanism) | Moderate (mechanism established, clinical relevance unknown) |
| 10 mcg/kg effective dose in rats | Replicated rat studies across multiple injury models | Positive | High (in rats) |
| Human dose of 200 to 500 mcg is effective | Researcher convention, no human RCT | Unknown | Very Low |
| Oral route reaches systemic circulation | Animal data; no human PK study | Uncertain | Low |
| Long-term safety in humans | No data | Unknown | Very Low |
| BPC-157 + TB-500 synergy | Theoretical / anecdotal; no controlled study | Speculative | Very Low |
Mechanism and Specific Numbers
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide comprising 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a region of human gastric juice protein BPC. Its molecular weight is 1419.53 Da.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Mechanistically, published animal studies have shown BPC-157 to:
- Upregulate vascular endothelial growth factor (VEGF) expression, promoting angiogenesis in wound beds.
- Increase expression of growth hormone receptor (GHR) in tendon fibroblasts, potentially amplifying GH signaling locally (Sikiric et al., multiple publications).
- Modulate nitric oxide (NO) synthesis pathways, which influences vasodilation and tissue perfusion.
- Interact with the dopaminergic and serotonergic systems in CNS models, though the relevance to dosing in peripheral injury is unclear.
What this mechanism does NOT prove: Upregulating VEGF in animal wound models does not demonstrate that the same concentrations are achieved in human tissue at the doses being used, nor that the same signaling cascades are activated identically in humans. VEGF upregulation also raises a theoretical, unresolved oncological concern that commodity pages almost universally omit.
BPC-157 Dosage Chart: Routes, Goals, and Conventions
| Use Context | Route | Dose Per Injection | Frequency | Typical Duration | Evidence Basis |
|---|---|---|---|---|---|
| Acute musculoskeletal injury | Subcutaneous (near site) | 250 to 500 mcg | Once daily | 4 to 8 weeks | Animal extrapolation |
| Tendon/ligament repair | Subcutaneous or intramuscular | 250 to 500 mcg | Once to twice daily | 4 to 12 weeks | Animal extrapolation |
| GI healing / gut permeability | Oral (capsule or dissolved) | 500 mcg, 1 mg | Once to twice daily | 4 to 8 weeks | Animal extrapolation; bioavailability unquantified |
| Conservative / first-time use | Subcutaneous | 200 to 250 mcg | Once daily | 2 weeks assessment, extend if tolerated | Convention / harm reduction |
BPC-157 Dosage Per Body Weight: The Allometric Math
The most frequently cited animal dose is approximately 10 mcg/kg in rats. To translate this to humans, the standard allometric scaling method uses a body surface area correction factor. The FDA-recognized interspecies scaling factor from rat to human is approximately 6.2 (based on Km factors: rat Km = 6, human Km = 37).
Human equivalent dose (HED) = Animal dose (mcg/kg) / 6.2
HED = 10 mcg/kg / 6.2 = approximately 1.6 mcg/kg
| Body Weight | Allometric HED (1.6 mcg/kg) | Researcher Convention Range | Discrepancy Factor |
|---|---|---|---|
| 60 kg (132 lb) | ~96 mcg | 200 to 500 mcg | 2 to 5x higher than HED |
| 75 kg (165 lb) | ~120 mcg | 200 to 500 mcg | 1.7 to 4x higher than HED |
| 90 kg (200 lb) | ~144 mcg | 250 to 500 mcg | 1.7 to 3.5x higher than HED |
| 110 kg (242 lb) | ~176 mcg | 300 to 500 mcg | 1.7 to 2.8x higher than HED |
The practical takeaway: researcher convention doses are consistently 2 to 5x higher than what strict allometric scaling predicts. This is not unusual (allometric scaling is an imperfect approximation), but it means dosing is operating well above the theoretical minimum effective range without any human efficacy or safety data to anchor the upper limit.
BPC-157 + TB-500 Stack Dosage
TB-500 is a synthetic fragment of Thymosin Beta-4 (the active region Ac-SDKP). The rationale for stacking with BPC-157 is mechanistic overlap: both promote tissue repair through angiogenesis and actin/cell-migration pathways, potentially via complementary rather than redundant mechanisms. This rationale is theoretical. No published controlled study has examined the combination.
| Phase | BPC-157 Dose | TB-500 Dose | Frequency | Duration |
|---|---|---|---|---|
| Loading | 250 to 500 mcg/day | 2 to 2.5 mg | BPC-157 daily; TB-500 2 to 3x/week | 4 to 6 weeks |
| Maintenance | 250 mcg/day | 2 mg | BPC-157 daily or 5x/week; TB-500 once weekly | 4 to 6 weeks |
| Off cycle | None | None | -- | 4+ weeks minimum |
Pre-blended BPC-157 + TB-500 vials are sold by some vendors. These convenience products raise an additional formulation concern: the two peptides may have different optimal reconstitution concentrations and storage stability profiles, and combining them into one vial has not been studied for compatibility or stability.
What Most BPC-157 Dosage Pages Get Wrong
This is the section commodity pages skip entirely.
1. Treating convention as data. The 250 to 500 mcg figure originated from researcher communities extrapolating loosely from animal work, not from a dose-finding study. It spread through forums and was then reverse-cited as if validated. There is no Goldilocks evidence for this range in humans.
2. Ignoring the VEGF/oncology signal. BPC-157 upregulates VEGF. VEGF promotes new blood vessel growth. In healthy wound healing, this is desirable. In a person with an undiagnosed or subclinical tumor, promoting angiogenesis is the mechanism by which tumors recruit blood supply. No study has examined BPC-157 in a cancer context, which means the risk has not been ruled out, not that it has been shown safe. Every page that omits this is prioritizing engagement over accuracy.
3. Equating oral and injectable bioavailability. Animal data suggests BPC-157 may exert local effects on GI mucosa when taken orally, but systemic plasma levels after oral dosing have not been quantified in humans. Peptides of this size are typically susceptible to proteolytic degradation in the GI tract. Claiming oral dosing is equivalent to subcutaneous is not supported.
4. Omitting purity variance. Research chemical vendors are not FDA-regulated. Independent testing of research peptides has found significant batch-to-batch purity variation and, in some cases, contaminants. A product labeled 5 mg may contain substantially less active peptide.
5. Ignoring the 2023-2024 FDA enforcement action. The FDA placed BPC-157 on the list of substances that may not be used in compounded medications, citing lack of clinical investigation. This has legal and supply-chain implications that dosage-only pages routinely omit.
The Chemistry Behind Storage and Stability Rules
BPC-157, like most peptides, degrades through several pathways that explain every storage rule you will encounter:
Hydrolysis: Peptide bonds (amide bonds) between amino acids react with water molecules. This is accelerated by heat, acidic or basic pH extremes, and prolonged exposure. Lyophilized (freeze-dried) powder is protected from hydrolysis because water activity is near zero. Once reconstituted, the clock starts. This is why reconstituted BPC-157 should be refrigerated and used within roughly 28 to 30 days; beyond this, hydrolytic degradation becomes meaningful, though the exact rate at 4 degrees Celsius has not been published for BPC-157 specifically.
Oxidation: Peptides with susceptible amino acid residues can be oxidized by reactive oxygen species or dissolved oxygen. Light (particularly UV) catalyzes this reaction. This is why amber or opaque vials are used and why you keep reconstituted peptide away from light.
Aggregation: Peptides can self-associate into non-active aggregates, particularly when concentration is too high or temperature fluctuates. Repeated freeze-thaw cycles accelerate this. Each freeze-thaw cycle stresses the tertiary structure and can increase aggregation. Best practice is to aliquot reconstituted peptide into single-use volumes before freezing if you must freeze the reconstituted form.
Bacteriostatic water vs. sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable life of a reconstituted vial meaningfully beyond plain sterile water. This is the practical reason bacteriostatic water is strongly preferred for multi-dose reconstitution.
Honest Head-to-Head: BPC-157 vs. Real Alternatives
| Criterion | BPC-157 | NSAIDs (e.g., ibuprofen) | PRP (Platelet-Rich Plasma) | Corticosteroid Injection |
|---|---|---|---|---|
| Human RCT evidence | None | Extensive | Moderate (mixed results) | Extensive |
| Tendon healing signal | Strong in animals | May impair healing (COX inhibition) | Mixed in humans | Short-term pain relief; may impair long-term healing |
| GI protection | Strong in animals | GI damage (known risk) | Not applicable | GI risk with systemic use |
| Safety profile (human) | Unknown | Well-characterized | Good; autologous product | Well-characterized; risks with repeated use |
| Regulatory status (US) | Research chemical only | OTC / prescription approved | Procedure; FDA-cleared devices | Prescription approved |
| Cost | Moderate (research chemical) | Very low | High ($500, $2000/session) | Low, moderate with insurance |
| Where BPC-157 loses | -- | Evidence base, legality, cost | Evidence base, regulatory clarity | Evidence base, legality |
The honest verdict: for human musculoskeletal injury, NSAIDs and corticosteroids have human efficacy and safety data; BPC-157 does not. PRP is closer in regulatory ambiguity but has at least been studied in humans. BPC-157's animal data is genuinely compelling and mechanistically plausible, but compelling animal data has failed to translate to humans across many peptide and drug candidates throughout history.
Operational Label and COA Literacy
Reconstitution math: A standard vial contains 5 mg (5000 mcg) of lyophilized BPC-157. To achieve 250 mcg per 0.1 mL dose, add 2 mL of bacteriostatic water. Each 0.1 mL drawn in an insulin syringe = 250 mcg. To achieve 500 mcg per 0.1 mL, add 1 mL of bacteriostatic water. Confirm your math: (vial content in mcg) / (volume added in mL) = mcg/mL, then divide by 10 for mcg per 0.1 mL.
| Vial Size | Bacteriostatic Water Added | Concentration | Dose per 0.1 mL |
|---|---|---|---|
| 5 mg (5000 mcg) | 1 mL | 5000 mcg/mL | 500 mcg |
| 5 mg (5000 mcg) | 2 mL | 2500 mcg/mL | 250 mcg |
| 5 mg (5000 mcg) | 5 mL | 1000 mcg/mL | 100 mcg |
| 10 mg (10000 mcg) | 2 mL | 5000 mcg/mL | 500 mcg |
What a valid COA must include:
- HPLC purity: minimum 98% for research use.
- Mass spectrometry: must confirm molecular weight of 1419.53 Da. Without this, you cannot confirm the peptide sequence is correct.
- Endotoxin (LAL test): below 1 EU/mg. Endotoxin contamination causes fever and systemic inflammatory response.
- Testing lab: a named, US-based third-party analytical laboratory, not the vendor's in-house lab.
- Lot number that matches the vial label.
Signs of degraded product: Reconstituted BPC-157 should be clear and colorless. Cloudiness, particulate matter, or a yellow tint indicates degradation or contamination. Do not use.
FAQ
What is the standard BPC-157 dosage for humans?
No human RCT has established a standard dose. Researchers and clinicians extrapolating from rat studies typically use 200 to 500 mcg per injection, one to two times daily, injected subcutaneously or intramuscularly near the injury site. These figures are researcher-derived conventions, not FDA-approved dosing.
What is the BPC-157 dosage per body weight?
Rat studies used roughly 10 mcg/kg. Allometric scaling to humans using the standard 6.2 body surface area conversion factor yields approximately 1.6 mcg/kg. For a 90 kg (200 lb) person that is roughly 144 mcg, well below the 200 to 500 mcg convention most researchers use. The discrepancy is unresolved.
What is the BPC-157 dosage for a 200 lb male?
Allometric scaling from rat data gives approximately 140 to 150 mcg per dose. Empirical researcher convention is 250 to 500 mcg per dose. Neither figure is validated in a human trial. Most 200 lb researchers start at 250 mcg once daily and assess tolerance over two weeks before adjusting.
How long should a BPC-157 cycle last?
Animal studies used durations of 7 to 28 days for acute injury models. Human researcher convention is typically 4 to 12 weeks. There is no human data on optimal cycle length or long-term safety beyond these conventions.
What is the BPC-157 and TB-500 stack dosage?
A common researcher protocol pairs BPC-157 at 250 to 500 mcg per day with TB-500 at 2 to 2.5 mg two to three times per week for a loading phase of 4 to 6 weeks, then drops TB-500 to 2 mg once weekly for maintenance. No human trial has validated this combination.
Is oral BPC-157 dosage the same as injectable?
No. Oral bioavailability of BPC-157 has not been quantified in humans. Animal data suggests the peptide reaches GI tissue at meaningful concentrations orally, possibly via local mucosal absorption, but systemic levels after oral dosing are uncertain. Oral protocols use higher nominal doses (500 mcg to 1 mg) to attempt compensation, without validated rationale.
Where should BPC-157 be injected?
Subcutaneous injection near the site of injury is the most studied route in animals and is the conventional human researcher approach. Intramuscular injection is also used. Intravenous administration carries unknown risk and is not supported by safety data.
Does BPC-157 need to be refrigerated?
Lyophilized BPC-157 powder is stable at room temperature for short periods but is best stored at 2 to 8 degrees Celsius. Once reconstituted in bacteriostatic water, it should be refrigerated and used within 28 to 30 days. Exposure to light, heat, and repeated freeze-thaw cycles degrades the peptide bond structure.
What are the known side effects of BPC-157?
No human safety trial exists. Animal studies report a favorable safety profile. Anecdotal human reports include nausea, dizziness, and injection site reactions. Because BPC-157 upregulates growth factor pathways including VEGF, theoretical concern about promoting angiogenesis in pre-existing tumors exists and has not been ruled out in humans.
How do I read a BPC-157 COA to check purity?
Look for HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight (1419.53 Da for BPC-157), and endotoxin testing below 1 EU/mg. A COA without mass spec confirmation is insufficient. Third-party testing from a US-based analytical lab is the minimum acceptable standard.
Is BPC-157 legal to buy?
BPC-157 is not FDA-approved for any indication. As of 2023 to 2024, the FDA has taken enforcement action restricting its use in compounded medications. It is sold as a research chemical in the US, which means it cannot legally be marketed for human consumption. Regulatory status varies by country.
How does BPC-157 compare to standard anti-inflammatory drugs for injury?
NSAIDs have robust human RCT data for pain and inflammation reduction. BPC-157 has zero human RCT data. Animal data for BPC-157 shows compelling tendon and GI repair signals, but direct human comparison does not exist. NSAIDs win on evidence; BPC-157 is mechanistically interesting but unproven.
Sources
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612 to 1632.
- Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor. 2010;16(3):BR81 to 88.
- Brcic L, et al. "Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing." Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191 to 196.
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Current Neuropharmacology. 2016;14(8):857 to 865.
- US FDA. "Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers." July 2005. (Source of Km-based allometric scaling methodology.)
- US FDA. "Difficult-to-Compound Medications and 503A/503B Compounding Pharmacies." FDA enforcement communications, 2023 to 2024. (BPC-157 inclusion on Category 2 list.)
- Sikiric P, et al. "Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems." Current Neuropharmacology. 2016. (Mechanistic/CNS pathway data.)
- Reagan-Shaw S, Nihal M, Ahmad N. "Dose translation from animal to human studies revisited." FASEB Journal. 2008;22(3):659 to 661. (Allometric scaling methodology and Km factors.)
Footer Disclaimers
Platform: FormBlends is an information and education platform. This page does not constitute medical advice. Consult a licensed healthcare provider before using any peptide, research chemical, or compounded medication.
Research Compound: BPC-157 is sold as a research chemical in the United States. It is not FDA-approved for any medical indication and may not legally be marketed for human consumption. The information on this page describes researcher conventions and animal-derived extrapolations only.
Results: Individual results, if any, will vary. The evidence base for BPC-157 in humans is absent. Claims of efficacy are speculative and are not endorsed by FormBlends or any regulatory body.
Trademark: All product names, brands, and trademarks mentioned are the property of their respective owners. FormBlends is not affiliated with any manufacturer or vendor of BPC-157 or TB-500.